Biotransformation of furaltadone by pig hepatocytes andSalmonella typhimuriumTA 100 bacteria, and the formation of protein-bound metabolites
- 1 January 1994
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 24 (8) , 713-727
- https://doi.org/10.3109/00498259409043272
Abstract
1. The major metabolite resulting from the biotransformation of furaltadone (5-morpholinomethyl-3-[5-nitrofurfurylidene-amino]-2-oxazolidinone) by pig hepatocytes was shown to result from the N-oxidation of the tertiary nitrogen in the morpholino-ring, leaving the nitrofuran ring unchanged. 2. No evidence could be obtained for the formation of an open-chain cyano-metabolite, a minor metabolite in the case of the related nitrofuran drug furazolidone (N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidinone). This metabolite was the major metabolite, following incubation of furaltadone and furazolidone with Salmonella typhimurium bacteria. 3. The N-oxide was not further metabolized by pig hepatocytes or bacteria, and gave negative test results in the Ames-test (TA 100, no S9-mix) at the highest tested dose of 1 μg/plate. Furaltadone gave a positive result at 10 ng/plate. 4. The biotransformation of both drugs by pig hepatocytes and bacteria resulted in the formation of protein-bound metabolites, with no clear quantitative differences between the two drugs. The intact 3-amino-2-oxazolidinone (AOZ) and 5-morpholinomethyl-3-amino-2-oxazolidinone (AMOZ) side-chains of furazolidone and furaltadone, respectively, could be released from these metabolites by mild acid treatment. 5. Hepatocytes incubated with the AMOZ side-chain of furaltadone showed a decreased monoamine oxidase activity at high dose levels (IC50 3.7 mM), whereas exposure to the AOZ side-chain of furazolidone resulted in a clear inhibition at 10000-fold lower concentrations (IC50 0.5μM). In the presence of 1% dimethylsulphoxide (DMSO), the MAO-inhibition by AMOZ and especially AOZ was remarkably reduced. 6. It is concluded that protein-bound metabolites containing an intact and releasable side-chain might be present in tissues of animals treated with furaltadone. However, these residues might be of less toxicological concern than those of furazolidone.Keywords
This publication has 23 references indexed in Scilit:
- Depletion of protein‐bound furazolidone metabolites containing the 3‐amino‐2‐oxazolidinone side‐chain from liver, kidney and muscle tissues from pigsFood Additives & Contaminants, 1992
- Study on the role of glutathione in the biotransformation and toxicity of furazolidone using pig hepatocytesToxicology in Vitro, 1992
- Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidoneFood and Chemical Toxicology, 1991
- The use of porcine hepatocytes for biotransformation studies of veterinary drugsXenobiotica, 1989
- Identification of a reactive intermediate of furazolidone formed by swine liver microsomesChemico-Biological Interactions, 1987
- The elimination of furazolidone and its open-chain cyano-derivative from adult swineXenobiotica, 1987
- Kinetics of14C‐furazolidone in piglets upon oral administration during 10 days and its interaction with tissue macro‐moleculesFood Additives & Contaminants: Part A, 1986
- Rapid colorimetric assay for cell growth and survivalJournal of Immunological Methods, 1986
- Activation of mutagens by hepatocytes and liver 9000 × g supernatant from human origin in the Salmonella typhimurium mutagenicity assayMutation Research/Environmental Mutagenesis and Related Subjects, 1986
- Mutagenicity of nitrofuran derivatives: ReviewEnvironmental Mutagenesis, 1983